skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Refametinib (Code C74059)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Refametinib

Definition: An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.

Display Name: Refametinib

Label: Refametinib

NCI Thesaurus Code: C74059 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2346909  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
BAY86-9766
BAY 869766
MEK Inhibitor RDEA119
RDEA119
Refametinib
REFAMETINIB

External Source Codes: 
CAS Registry Number 923032-37-5 (see NLM ChemIDplus info)
FDA UNII Code JPX07AFM0N
PDQ Closed Trial Search ID 589128
PDQ Open Trial Search ID 589128 (check for NCI PDQ open clinical trial info)
UMLS CUI C2346909

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C19H20F3IN2O5S
code C74059
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name MEK_Inhibitor_RDEA119
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74059

Mainbox Bottom